Atara Biotherapeutics Inc (NASDAQ:ATRA)
| 15.27 Delayed Data As of Jan 26 |  +0.17 / +1.13%Today’s Change | 11.81 Today|||52-Week Range 21.85 | -3.11% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.2B |
Company Description
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
Contact Information
Atara Biotherapeutics, Inc. 611 Gateway Boulevard South San Francisco California 94080 |
Employees
Shareholders
| Other institutional | 57.55% |
| Mutual fund holders | 45.33% |
| Individual stakeholders | 11.65% |
Top Executives
| Pascal Touchon | President, Chief Executive Officer & Director |
| Joseph Newell | Chief Operating Officer & Executive Vice President |
| Utpal Koppikar | Chief Financial Officer & Senior Vice President |
| Manher AJ Joshi | Chief Medical Officer |
| Jakob Dupont | Global Head-Research & Development |
